Dr Ari Tolonen, the former CEO, will continue as a CSO and the Head of In vitro metabolism and biotransformations. These positive changes reflect the success of the Admescope team over the past decade and will allow Ari to focus on excellence in science and R&D for the future growth of the portfolio.
Outi is thrilled to join the team and contribute to the success of our customers. She comes in with extensive preclinical drug development and international CRO managerial experience, most recently having served as a Senior Director Alliance Management at Charles River Laboratories. Her scientific background is in molecular pharmacology, complementary to the portfolio of Admescope and Symeres group of which Admescope has been part since November 2020.
All the best to Outi and good luck in her new venture.